<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137833">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01869881</url>
  </required_header>
  <id_info>
    <org_study_id>YCM009</org_study_id>
    <nct_id>NCT01869881</nct_id>
  </id_info>
  <brief_title>Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)</brief_title>
  <official_title>Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have
      Type 2 Diabetes by using sarpogrelate and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>treatment period(24 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>adverse event and rate of adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR(Urine Albumin/Creatinine ratio)</measure>
    <time_frame>treatment period(24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>change of percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR(Urine Albumin/Creatinine ratio)</measure>
    <time_frame>Treatment period(24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>improvement efficiency rate of ACR comparing to baseline Definition of improvement efficiency : ACR become normal(&lt;20mg/g Cr) or ACR is decreased more than 50% comparing to data before taking IP(Investigators' product)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary 5-HIAA(5-Hydroxyindoleacetic acid), type 4 collagen</measure>
    <time_frame>treatment period(24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>changes comparing to baseline data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR(Urine Albumin/Creatinine ratio)</measure>
    <time_frame>treatment period(24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>improved amount comparing to baseline data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR(Urine Albumin/Creatinine ratio)</measure>
    <time_frame>treatment period(24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>rate of normalized ACR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>treatment period(24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>improved amount of Creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR(Protein to Creatinine ratio in Urine)</measure>
    <time_frame>treatment period(24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>improved rate comparing to baseline data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Sarpogrelate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anplag(Sarpogrelate)</intervention_name>
    <description>Sarpogrelate 100mg 2 tablets, bid, 400mg/day</description>
    <arm_group_label>Sarpogrelate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 100mg 2 tablets, bid, 400mg/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  person who signed on ICF

          -  Type 2 diabetic patient who have microalbuminuria or overt proteinuria

          -  In case of hypertension patients, who keep the same medication steadily over last 4
             weeks

        Exclusion Criteria:

          -  patients who have hypersensitivity on sarpogrelate or other salicylic acid

          -  patients who should keep the antiplatelet agent because of acute cardiac disease or
             peripheral vein disease

          -  patients who took other anticoagulant agent within 1 month

          -  patient who take ACEI OR ARB but not controlled(over 150/100mmHg)

          -  Type 1 diabetes patients

          -  Patient who have cardiac or liver problem

          -  Cr: &gt;1.8mg/dl or GFR: &lt;40ml/min

          -  malignant tumor patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D.S Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Hospital, Anam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Ok Kim, RN</last_name>
    <email>gusdhr2532@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University, Anam</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Ok Kim, RN</last_name>
      <email>gusdhr2532@naver.com</email>
    </contact>
    <investigator>
      <last_name>D.S Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 4, 2013</lastchanged_date>
  <firstreceived_date>May 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
